


Form PTO-1595 (Rev. 10/02) OMB No. 0651-0027 (exp. 6/30/2005)		RECORDATION FORM COVER SHEET PATENTS ONLY		U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office	
To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.					
1. Name of conveying party(ies): Versicor Inc. Additional name(s) of conveying party(ies) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No			2. Name and address of receiving party(ies) Name: <u>Vicuron Pharmaceuticals Inc.</u> Internal Address: _____ _____ Street Address: <u>455 South Gulph Road</u> _____ City: <u>King of Prussia</u> State: <u>PA</u> Zip: <u>19406</u> Additional name(s) & address(es) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		
3. Nature of conveyance: <input type="checkbox"/> Assignment <input type="checkbox"/> Merger <input type="checkbox"/> Security Agreement <input checked="" type="checkbox"/> Change of Name <input type="checkbox"/> Other _____ Execution Date: <u>03/21/2003</u>					
4. Application number(s) or patent number(s): If this document is being filed together with a new application, the execution date of the application is: _____ A. Patent Application No.(s) <u>09/744247</u> B. Patent No.(s) <u>4935238</u> Additional numbers attached? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No					
5. Name and address of party to whom correspondence concerning document should be mailed: Name: <u>Mark E. Miller, Esq.</u> Internal Address: <u>O'Melveny & Myers LLP</u> _____ Street Address: <u>275 Battery Street</u> <u>26th Floor</u> City: <u>San Francisco</u> State: <u>CA</u> Zip: <u>94111</u>			6. Total number of applications and patents involved: <u>33</u> 7. Total fee (37 CFR 3.41).....\$ <u>1340.00</u> <input type="checkbox"/> Enclosed <input checked="" type="checkbox"/> Authorized to be charged to deposit account IN THE SUM OF \$515.00 8. Deposit account number: <u>50-0639</u>		
DO NOT USE THIS SPACE					
9. Signature. <div style="display: flex; justify-content: space-between;"> <div style="width: 30%;"> <u>Mark E. Miller</u> Name of Person Signing </div> <div style="width: 40%; text-align: center;">  Signature </div> <div style="width: 30%; text-align: right;"> <u>January 14, 2004</u> Date </div> </div> <div style="text-align: right; margin-top: 5px;">Total number of pages including cover sheet, attachments, and documents: <u>13</u></div>					

CH \$1320.00 500639 09744247

UNITED STATES

Title: ANTIBIOTIC A 40926 COMPLEX AND ITS PURE FACTORS
Inventors: E. Selva, et al
Application Date: October 9, 1985
Patent Number: 4935238
Grant Date: June 19, 1990

Title: SELECTIVE INCREASE OF RATIO OF SINGLE MAJOR COMPONENTS (A2 & A3) OF ANTIBIOTICS A/16686
Inventors: G. Lancini, et al
Application Date: December 18, 1997
Patent Number: 5925550
Grant Date: July 20, 1999

Title: SELECTIVE INCREASE OF RATIO OF SINGLE MAJOR COMPONENTS OF A40926 COMPLEX
Inventors: E. Selva, et al
Application Date: September 10, 1987
Patent Number: 5843679
Grant Date: December 1, 1998

Title: GLYCOPEPTIDES ANTIBIOTICS: DEACYL A40926
Inventors: E. Selva, et al
Application Date: June 1, 1995
Patent Number: 5567676
Grant Date: October 22, 1996

Title: NOVEL HYDROGENATED DERIVATIVES OF ANTIBIOTIC A/16686
Inventors: R. Ciabatti, et al
Application Date: December 5, 1988
Patent Number: 5108988
Grant Date: April 28, 1992

Title: ANTIBIOTIC A/16686 RECOVERY PROCESS
Inventors: E. Restelli, et al
Application Date: May 18, 1995
Patent Number: 5539087
Grant Date: July 23, 1996

Title: ANTIBIOTIC GE 2270
Inventors: E. Selva, et al
Application Date: June 11, 1991
Patent Number: 5202241
Grant Date: April 13, 1993

Title: ANTIBIOTIC GE 2270
Inventors: E. Selva, et al
Application Date: October 14, 1992
Patent Number: 5322777
Grant Date: June 21, 1994

Title: NEW SUBSTITUTED ALKYLAMIDE DERIVATIVES OF TEICOPLANIN
Inventors: A. Malabarba, et al
Application Date: June 5, 1995
Patent Number: 5500410
Grant Date: March 19, 1996

Title: ANTIBIOTIC GE 2270 FACTORS A1, A2, A3, and H
Inventors: E. Selva, et al
Application Date: July 2, 1990
Patent Number: 5139778
Grant Date: August 18, 1992

Title: ANTIBIOTIC GE 2270 FACTORS A1, A2, A3, and H
Inventors: E. Selva, et al
Application Date: June 7, 1995
Patent Number: 5547666
Grant Date: August 20, 1996

Title: PENTAPEPTIDE ANTIBIOTICS DERIVED FROM DALBAHEPTIDES
Inventors: A. Malabarba, et al
Application Date: May 15, 1995
Patent Number: 5602229
Grant Date: February 11, 1997

Title: PENTAPEPTIDE ANTIBIOTICS DERIVED FROM DALBAHEPTIDES
Inventors: A. Malabarba, et al
Application Date: May 31, 1995
Patent Number: 5648456
Grant Date: July 15, 1997

Title: ANTIBIOTIC GE 2270 FACTORS B1, B2, C1, C2, D1, D2, E and T
Inventors: E. Selva, et al
Application Date: June 2, 1995
Patent Number: 5747295
Grant Date: May 5, 1998

Title: ANTIBIOTIC GE 2270 FACTORS B1, B2, C1, C2, D1, D2, E and T
Inventors: E. Selva, et al
Application Date: June 5, 1995
Patent Number: 5843890
Grant Date: December 1, 1998

Title: TETRAPEPTIDES DERIVING FROM DALBAHEPTIDE ANTIBIOTICS
Inventors: A. Malabarba, et al
Application Date: February 17, 1995
Patent Number: 5644025
Grant Date: July 1, 1997

Title: TETRAPEPTIDES DERIVING FROM DALBAHEPTIDE ANTIBIOTICS
Inventors: A. Malabarba, et al
Application Date: June 5, 1995
Patent Number: 5684127
Grant Date: November 4, 1997

Title: AMIDES OF ANTIBIOTICS GE 2270 FACTORS
Inventors: P. Tavecchia, et al
Application Date: January 2, 1992
Patent Number: 5599791
Grant Date: February 4, 1997

Title: HEXAPEPTIDES DERIVING FROM AGLUCOTEICOPLANIN AND A PROCESS FOR PREPARING THEM
Inventors: A. Malabarba, et al
Application Date: June 26, 1994
Patent Number: 5438117
Grant Date: August 1, 1995

Title: ANTIBIOTIC A 40926 ESTER DERIVATIVES
Inventors: R. Hermann, et al.
Application Date: May 22, 1995
Patent Number: 5606036
Grant Date: February 25, 1997

Title: ANTIBIOTIC GE 2270 FACTOR 2A
Inventors: E. Selva, et al
Application Date: April 21, 1995
Patent Number: 5514649
Grant Date: May 7, 1996

Title: AMIDE DERIVATIVES OF ANTIBIOTIC A 40926
Inventors: A. Malabarba, et al
Application Date: April 30, 1996
Patent Number: 5750509
Grant Date: May 12, 1998

Title: PROCESS FOR SELECTIVE PRODUCTION FOR ANTIBIOTIC GE 2270 FACTOR A
Inventors: A. Rizzo, et al
Application Date: September 30, 1997
Patent Number: 5882900
Grant Date: March 16, 1999

Title: BASIC PROLINE-AMIDE DERIVATIVES OF GE 2270 and GE 2270-LIKE ANTIBIOTICS
Inventors: S. Lociuero, et al
Application Date: February 1, 1996
Patent Number: 6143739
Grant Date: November 7, 2000

Title: SYNTHETIC AGLUCODALBAHEPTIDE ANTIBIOTICS
Inventors: A. Malabarba, et al
Application Date: April 14, 1994
Patent Number: 5674840
Grant Date: October 7, 1997

Title: IMPROVED CHEMICAL PROCESS FOR PREPARING AMIDE DERIVATIVES OF ANTIBIOTIC
A 40926

Inventors: G. Panzone, et al
Application Date: April 15, 1997
Patent Number: 6218505 B1
Grant Date: April 17, 2001

Title: BASIC OXAZOLINE-AMIDE DERIVATIVES OF GE 2270 and GE 2270-LIKE ANTIBIOTICS

Inventors: S. Lociuero, et al
Application Date: July 31, 1997
Patent Number: 5891869
Grant Date: April 6, 1999

Title: DERIVATIVES OF ANTIBIOTIC GE 2270 FACTORS C2A, D2 and E

Inventors: S. Lociuero, et al
Application Date: February 12, 1997
Patent Number: 6008225
Grant Date: December 28, 1999

Title: NEW INJECTABLE FORMULATIONS (OF RAMOPLANIN)

Inventors: F. Parenti, et al
Application Date: January 30, 2001
Application Number: 09/744247

Title: METHOD FOR TRANSFERRING THE CAPABILITY TO PRODUCE A NATURAL PRODUCT
FROM AN ORIGINAL MICROORGANISM TO A SUITABLE HOST

Inventors: S. Donadio, et al
Application Date: June 14, 1999
Application Number: 09/720314

Title: ANTIBIOTICS GE 23077 PHARMACEUTICALLY ACCEPTABLE SALTS AND
COMPOSITIONS, AND USE THEROF

Inventors: E. Selva, et al
Application Date: 11/9/01
Application Number: 09/986540

Title: DINUCLEOSIDE-5',5'-PYROPHOSPHATES ADMINISTERED TO TREAT HIV

Inventors: De Flora, et al
Application Date: July 1, 1998
Patent Number: 6080731
Grant Date: June 27, 2000

Title: DINUCLEOSIDE-5',5'-PYROPHOSPHATES

Inventors: De Flora, et al
Application Date: January 14, 1997
Patent Number: 6040297
Grant Date: March 21, 2000

Delaware

PAGE 1

The First State

I, HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF OWNERSHIP, WHICH MERGES:

"VICURON PHARMACEUTICALS INC.", A DELAWARE CORPORATION,
WITH AND INTO "VERSICOR INC." UNDER THE NAME OF "VICURON PHARMACEUTICALS INC.", A CORPORATION ORGANIZED AND EXISTING UNDER THE LAWS OF THE STATE OF DELAWARE, AS RECEIVED AND FILED IN THIS OFFICE THE TWENTY-FIRST DAY OF MARCH, A.D. 2003, AT 4:02 O'CLOCK P.M.

AND I DO HEREBY FURTHER CERTIFY THAT THE EFFECTIVE DATE OF THE AFORESAID CERTIFICATE OF OWNERSHIP IS THE TWENTY-SIXTH DAY OF MARCH, A.D. 2003, AT 12:01 O'CLOCK A.M.



Harriet Smith Windsor

Harriet Smith Windsor, Secretary of State

2503398 8100M

AUTHENTICATION: 2391595

030279448

DATE: 04PATENT

REEL: 014250 FRAME: 0957

STATE OF DELAWARE
SECRETARY OF STATE
DIVISION OF CORPORATIONS
FILED 04:02 PM 03/21/2003
030191900 - 2503398

CERTIFICATE OF OWNERSHIP AND MERGER

MERGING

VICURON PHARMACEUTICALS INC.

INTO

VERSICOR INC.

Pursuant to Section 253 of the General Corporation Law of
the State of Delaware

In accordance with Section 253 of the General Corporation Law of the State of Delaware, Versicor Inc., a Delaware corporation (this "Corporation"), hereby certifies the following information relating to the merger (the "Merger") of Vicuron Pharmaceuticals Inc., a Delaware corporation (the "VPI"), with and into this Corporation whereby this Corporation shall be the surviving corporation (the "Surviving Corporation"), which shall succeed to and assume all of the rights and obligations of this Corporation as well as the assets and liabilities of VPI:

First: That the name and state of incorporation of this Corporation and VPI which are the constituent corporations in the Merger are:

NAME

STATE OF INCORPORATION

Vicuron Pharmaceuticals Inc.
Versicor Inc.

Delaware
Delaware

Second: That this Corporation owns all of the issued and outstanding capital stock of
VPI

Third: That the Board of Directors of this Corporation by resolutions adopted on March 6, 2003, determined, among other things, to (i) consummate the Merger whereby this Corporation shall be the Surviving Corporation, which shall succeed to and assume all of the rights and obligations of this Corporation as well as the assets and liabilities of VPI, (ii) change its name to "Vicuron Pharmaceuticals Inc." by amending its certificate of incorporation, which resolutions are set forth below:

WHEREAS, this Corporation desires to change its name from
"Versicor Inc." to "Vicuron Pharmaceuticals Inc."; and

WHEREAS, this Corporation lawfully owns all the outstanding stock of Vicuron Pharmaceuticals Inc., a Delaware corporation ("VPI"); and

WHEREAS, pursuant to Section 253 of the General Corporation Law of the State of Delaware, this Corporation desires to merge into itself VPI (the "VPI Merger") and this Corporation shall be the surviving corporation (the "Surviving Corporation"), which shall succeed to and assume all of the rights and obligations of this Corporation as well as the assets and liabilities of VPI; and

WHEREAS, this Corporation desires that the VPI Merger shall be effective on March 26, 2003 or such other time as the Chief Executive Officer of this Corporation shall determine (the "VPI Effective Time"); and

WHEREAS, this Corporation shall file with the Secretary of State of the State of Delaware a Certificate of Ownership and Merger (the "Certificate of Ownership and Merger") so that as a result of the VPI Merger and from and after the VPI Effective Time, the name of the Surviving Corporation shall be "Vicuron Pharmaceuticals Inc."

WHEREAS, this Corporation desires that the certificate of incorporation of the Surviving Corporation shall be this Corporation's Fourth Amended and Restated Certificate of Incorporation, as amended by the Certificate of Ownership and Merger; and

NOW, THEREFORE, BE IT RESOLVED, that upon the VPI Effective Time, this Corporation shall consummate the VPI Merger with VPI and the Surviving Corporation shall succeed to and assume all of the rights and obligations of this Corporation as well as the assets and liabilities of VPI; and

RESOLVED FURTHER, that upon the effectiveness of the Merger, the name of this Corporation shall be changed to "Vicuron Pharmaceuticals Inc." and Article I of the Fourth Amended and Restated Certificate of Incorporation of this Corporation shall be amended to read as follows:

"ARTICLE I

The name of the Corporation is Vicuron Pharmaceuticals Inc."; and

RESOLVED FURTHER, that the Chief Executive Officer and Chief Financial Officer of this Corporation (the "Authorized Officers"), or each of them individually, be, and they hereby are, directed to make and execute, under the corporate seal of this Corporation, the Certificate of

Ownership and Merger setting forth a copy of these resolutions to so merge VPI into this Corporation and assume VPI's liabilities and obligations, and the date of adoption thereof, and to cause the same to be filed in the office of the Secretary of State of the State of Delaware and a certified copy thereof in the office of the Recorder of Deeds of the appropriate county in the State of Delaware; and

RESOLVED FURTHER, that the Authorized Officers, or each of them individually, be, and they hereby are, authorized and directed to do all acts and things whatsoever, whether within or without the State of Delaware, which may be necessary or proper to effect the Merger and change of name.

Fourth: That the Fourth Amended and Restated Certificate of Incorporation of this Corporation as in effect immediately prior to the Merger shall be the Fourth Amended and Restated Articles of Incorporation of the Surviving Corporation, until thereafter amended in accordance with its terms and the General Corporation Law of the State of Delaware, except that Article I of the Fourth Amended and Restated Certificate of Incorporation of the Surviving Corporation shall be amended to read as follows:


"ARTICLE I

The name of the Corporation is "Vicuron Pharmaceuticals Inc."

Fifth: That in accordance with Section 103(d) of the General Corporation Law of the State of Delaware the Merger shall become effective upon 12:01 a.m. (Eastern Standard Time) on March 26, 2003.

IN WITNESS WHEREOF, the undersigned corporation has caused this Certificate of Ownership and Merger to be executed in its corporate name this 21st day of March, 2003.

VERSICOR INC.,
a Delaware corporation

By: 
George F. Horner III
President and Chief Executive Officer

LA1:998623



O'MELVENY & MYERS LLP

LOS ANGELES
CENTURY CITY
IRVINE SPECTRUM
NEWPORT BEACH
NEW YORK
SILICON VALLEY
TYSONS CORNER

Embarcadero Center West
275 Battery Street
San Francisco, California 94111-3344

TELEPHONE (415) 984-8700
FACSIMILE (415) 984-8701
INTERNET www.omm.com

WASHINGTON, D.C.
BEIJING
HONG KONG
LONDON
SHANGHAI
TOKYO

January 14, 2004

OUR FILE NUMBER
892280-006

VIA FACSIMILE 703.306.5995

WRITER'S DIRECT DIAL
(415) 984-8767

Mail Stop Assignment Recordation Services
Director of the U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

WRITER'S E-MAIL ADDRESS
nbeck@omm.com

Re: *Fax-n-File Recording of Name Change - Patents*

Dear Sirs:

On April 24, 2003, we submitted a Recordation Cover Sheet, a Schedule of Patents, and a check in the sum of \$825.00 requesting the recordal of the name change of Versicor Inc. to Vicuron Pharmaceuticals Inc. for the scheduled patents. Today we contacted the Assignment Division to inquire about the status of the name change recordal and were advised that recordal was refused (since formal name change documents were not submitted with the Recordation Cover Sheet and/or insufficient payment) and a Notice of Non-Recordal issued in October 2003. Unfortunately, we have not received and/or been able to locate the Notice of Non-Recordal.


Therefore, we have prepared and transmit herewith new documents for recordal. We understand that the our previously submitted check in the sum of \$825.00 is still on deposit. Authorization to charge our deposit account the additional fee of \$515.00 (\$495.00 filing fee plus \$40.00 fax fee) is provided.

Attached hereto for recording are the following documents:

- 1) Recordation Cover Sheet for name change;
- 2) Schedule of Patents and Patent Applications for recording of name change; and
- 3) Certificate of Ownership and Merger Merging Vicuron Pharmaceuticals Inc. and Versicor Inc.

Please contact us if you have any questions or require additional information regarding this request for recording.

Very truly yours,



Nina D. Beck
IP Case Manager

NDB:wp